Peter Kraft

@peter-kraft.bsky.social

Cancer epidemiologist, statistical geneticist, biostatistician. National Cancer Institute, Harvard. Views my own.

Introducing the 𝐎𝐩𝐞𝐧 𝐒𝐜𝐡𝐨𝐥𝐚𝐫𝐬𝐡𝐢𝐩 𝐓𝐫𝐚𝐢𝐧𝐢𝐧𝐠 𝐟𝐨𝐫 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡𝐞𝐫𝐬 𝐒𝐞𝐫𝐢𝐞𝐬 We’re starting with 2 online courses, with more on the way: → Fundamentals of Open Scholarship > bit.ly/4vYZVjh → Preregistration and Reregistration Reports > bit.ly/48sPpXE 🧵 (1/6)

📣 𝐖𝐞’𝐫𝐞 𝐡𝐢𝐫𝐢𝐧𝐠 𝐚 𝐩𝐨𝐬𝐭𝐝𝐨𝐜 𝐢𝐧 𝐩𝐨𝐩𝐮𝐥𝐚𝐭𝐢𝐨𝐧 & 𝐬𝐭𝐚𝐭𝐢𝐬𝐭𝐢𝐜𝐚𝐥 𝐠𝐞𝐧𝐞𝐭𝐢𝐜𝐬! 🌍📈🧬 If you’re finishing a PhD (or know someone who is) and want to work on complex trait biology + 𝑟𝑒𝑎𝑙-𝑤𝑜𝑟𝑙𝑑 𝑖𝑚𝑝𝑎𝑐𝑡, read on 👇

🎉New preprint: Phenome-derived polygenic scores and social determinants jointly shape context-dependent disease risk. We evaluate disease risk along 2 complementary axes: • how genetic liability is represented • the social context in which it is expressed

Bild
medRxivpreprint@medrxivpreprint.bsky.social · 4mo ago

Phenome-derived polygenic scores and social determinants jointly shape context-dependent disease risk https://www.medrxiv.org/content/10.64898/2026.04.16.26351039v1

Ooh sorry to miss in person but glad it will be recorded. Having embarrassed myself recently blathering on about how my one undergrad “Theater of Bertolt Brecht” class formed my perspective on AI (thanks umich rc!), it will be nice to hear from folks who’ve actually studied and thought about this.

Alondra Nelson@alondra.bsky.social · 3mo ago

An #AI event with #PhiBetaKappa next Tuesday in San Diego, where I was elected to PBK. A full circle moment. Free with registration. Join us! www.eventbrite.com/e/the-human-...

Congrats and kudos to @xueyaowu.bsky.social for leading this collab with Joy Jiang, Graham Colditz, Rulla Tamimi & team—first of 🤞many projects to peek into the black box of AI mammogram risk models and see if they are telling us something about breast cancer epidemiology. 1/2

xueyaowu.bsky.social@xueyaowu.bsky.social · 4mo ago

Excited to share our recent paper in #npjBreastCancer! We investigated what drives the AI-generated mammogram risk score (MRS)—a texture feature that predicts breast cancer risk beyond breast density. A thread 👇 @peter-kraft.bsky.social

So this is a really important point- using AI to "detect" IPV without patients' consent or willing disclosure raises issues - why screen for IPV without a patient-centered framework? - what are health systems doing with these data? - how are patients being protected?

Oni Blackstock, MD MHS@oniblackstock.bsky.social · 4mo ago

One reason is that it takes away autonomy from the patient/client to disclose their experience of IPV. People experiencing IPV often strategize what to share and when. AI "disclosing" this takes away their autonomy and could put people at greater risk.

Looking forward to #AACR26 in San Diego in less than a week! Check out these presentations from our team, including the largest ever GWAS of breast cancer & AML and a hot-off-the-presses study of mutational patterns in triple-negative breast cancer.

List of abstracts, including times and program numbers.
.
Apr. 19, 2026, 4:35 PM - 4:50 PM
1381: The Confluence Project: Largest multi-ancestry genome-wide association study of breast cancer identifies 469 susceptibility loci in over two million participants African-ancestry Breast Cancer Genetic Consortium, Breast Cancer Association Consortium. Consortium of Investigators of Modifiers of BRCA1/2, Latin America Genomics of Breast Cancer Consortium, Male Breast Cancer Genetics Consortium, National Cancer Inst. Div. of Cancer Epidemiology & Genetics
.
Apr. 20, 2026, 9:00 AM - 12:00 PM
1481:	Integrative analysis identifies potential proteomic intermediates associated with renal cell carcinoma and its risk factors. Ibrahim Hossain Sajal, Andrew J. Song, Kevin M. Brown, Mitchell J. Machiela, Peter Kraft, Stephen J. Chanock, Mark P. Purdue, Diptavo Dutta
2090:	Modifiable lifestyle factors and immune gene expression in breast tumor and normal-adjacent tissue. Kristen D. Brantley, Cheng Peng, Clara Bodelon, Deborah A. Tadesse, Peter Kraft, Rulla M. Tamimi

Apr. 21, 2026, 2:00 PM - 5:00 PM
LB387: Genome-wide association study identifies germline susceptibility loci for acute myeloid leukemia. Xueyao Wu, Filip Pirsl, Gabrielle Schmidt, Maryam Rafati, Aurélie Vogt, Herbert Higson, Jia Liu, Jiahui Wang, Shilpa Gaddam, Shengchao Li, Wael Saber, Yung-Tsi Bolon, Steven Moore, Sharon A. Savage, Stephen Chanock, Stephen Spellman, Peter Kraft, Shahinaz M. Gadalla
LB391: Pre-diagnostic exposures, mutational signatures, and immune profiles in triple-negative breast cancer: An overview of the PREMISE-TN project. Deborah A. Tadesse, Clara Bodelon, Cheng Peng, Kristen D. Brantley, Margaux Delporte, Yujing J. Heng, Lauren Teras, Rulla M. Tamimi, Peter Kraft

I’m honored and excited to join the Board of Directors! IGES is home to such a vibrant and welcoming scientific community, I look forward to helping it continue to thrive! 💟🧬 Join us for IGES 2026 in beautiful Estérel, QC 🍁 Abstract submission is open until May 30 www.geneticepi.org/2026-annual-...

2026 Annual Meeting

geneticepi.org

International Genetic Epidemiology Society@geneticepi.bsky.social · 5mo ago

Congratulations to the winners of this year's IGES leadership elections! 🎉🎉🎉 • President Elect: Elizabeth Blue • Treasurer: Cheryl Cropp • Board of Directors: @lindakachuri.bsky.social and @burcudarst.bsky.social

Failure to understand that the fundamental principle of Mendelian randomization (MR) is of gene-environment equivalence contributes to the flood of nonsense MR papers that are appearing; Shah Ebrahim, Gib Hemani and I explain why in this short commentary. journals.plos.org/plosmedicine...

Gene-environment equivalence: The fundamental principle of Mendelian randomization

In this Perspective, George Davey Smith and colleagues outline how and why gene-environment equivalence, the fundamental principle of Mendelian Randomization (MR), must be properly applied and critica...

journals.plos.org

This was neat work by @nmancuso.bsky.social et al developing and benchmarking a new multi-ancestry fine-mapping method (“SuShiE”). I learned something about the performance of pooled v stratified analyses but still have some Qs. 1/n

Nature Genetics@natgenet.nature.com · last yr.

📢OUT TODAY @natgenet.nature.com 📰Improved multiancestry fine-mapping identifies cis-regulatory variants underlying molecular traits and disease risk. By @zeyunlu.bsky.social, @nmancuso.bsky.social and colleagues. ⬇️ www.nature.com/articles/s41...

An evergreen thread: Race/Ethnicity is *not the same* as genetics, and you can't use Race/Ethnicity as a sort of stand-in for genetics. These two concepts are connected via aspects like skin colour, but the connection is alot less profound and categorical than most people think.